CIDP to Unveil New Study Protocol at in-cosmetics Global 2018


Skin microbiome evaluation and the antipollution claim

Mauritius, 08 February 2017
CIDP, Centre International de Développement Pharmaceutique, a private and independent Contract Research Organisation (CRO), today announces its participation in In-Cosmetics Global 2018 from 17 - 19 April in Amsterdam. After successfully setting up its Unique Pollution Exposure System in 2017, for the standardization of the anti-pollution claim and having developed an ex vivo model, CIDP continues its innovative endeavour by offering the possibility of skin microbiome evaluation.

Skin Microbiota
It is now well established within the scientific communities that a well-balanced microbiota is essential for a healthy and beautiful skin. Just like the human gut, the skin contains a variety of microbial communities comprising of bacteria, fungi, yeast and viruses. Some of these are considered beneficial while others are considered harmful to the skin. However, it is important to have a good biodiversity and an evenness in the microbe's distribution to maintain a healthy skin.

Cosmetics products can help to maintain the skin healthy by:
  1. 1.    Maintaining a healthy well-balanced microbiome
  2. 2.    Having a Probiotic effect: improves the microbiota by the addition of living "good" bacteria or extracts from living bacteria
  3. 3.    Having a Prebiotic effect: actives which will rebalance the microbiota.
Many cosmetic brands have understood the opportunities that exist due to the connection between a healthy, beautiful skin and a balanced microbiome. Various cosmetics products have already been commercialised.

As an innovative CRO, CIDP is providing innovative solution to substantiate these claims. They are indeed providing study protocols that allow evaluation of skin microbiome by new methods such as 16S-rRNA Gene Sequencing, whereby bacteria can be identified to their specific genes.

On 17 April at 11:20am, Mrs Véronique NEWTON, R&D Laboratory Manager at CIDP, will present the company's standard protocols for objective substantiation of anti-pollution claims. She will also share more about CIDP's successful creation of an ex vivo model that mimics in vivo conditions.

Visitors can also find out more about CIDP's study protocol and full suite of services - which comprises research activities, in vitro testing, analytical chemistry, formulation, and clinical research - at Booth H150.

For more information, please visit

About Centre International de Développement Pharmaceutique (CIDP)
CIDP is a private and independent Contract Research Organisation (CRO) that conducts high-performing research and clinical activities for cosmetics, pharmaceutical and nutrition industries. The group serves clients with its full suite of services - comprising in vitro and ex vivo testing, analytical chemistry, formulation, and clinical research. Established in 2004, CIDP is a leading company in the field offering extensive scientific expertise in the dermo-cosmetics sector.

Earlier in 2017, CIDP unveiled its innovative study protocol for substantiating anti-pollution and blue light claims on cosmetic products. Since then, and recognized for its innovative researches, the company has developed an ex vivo model as an addition to its in vivo protocols. This new ex vivo model allows experiments to be conducted in conditions close to the in vivo model.

The geographical locations of CIDP's centres - in Mauritius, Brazil, India, Romania and Singapore - enable the company the access to a wide panel of patients. This allows the group to undertake multi-centric trials with a rapid recruitment process in a secured and adapted environment. Recognised for its expertise, CIDP works with the leaders of the cosmetics and pharmaceutical industry.

Having served the personal care market for nearly two decades, CIDP is familiar with manufacturers' research needs and well-versed with the techniques required. Our Preclinical Laboratory is GLP certified. CIDP is ISO 9001:2015 certified and GCP compliant.

For more information, please visit

« back